Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer

Authors

  • Christina Bjerre Sino-Danish Breast Cancer Research Centre at Section of Pathobiology, Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Oncology, Rigshospitalet – Copenhagen University Hospital, Copenhagen, Denmark
  • Ann Knoop Department of Oncology, Rigshospitalet – Copenhagen University Hospital, Copenhagen, Denmark
  • Karsten Bjerre Danish Breast Cancer Cooperative Group, Copenhagen, Denmark
  • Mathilde S. Larsen Department of Pathology, Herlev Hospital, Herlev, Denmark
  • Katrine L. Henriksen Breast Cancer Group, Unit of Cell Death and Metabolism, Danish Cancer Society Research Center, Denmark, Copenhagen
  • Maria B. Lyng Institute of Molecular Medicine, Department of Cancer and Inflammation Research, University of Southern Denmark, Odense, Denmark
  • Henrik J. Ditzel Institute of Molecular Medicine, Department of Cancer and Inflammation Research, University of Southern Denmark, Odense, Denmark
  • Birgitte B. Rasmussen Department of Pathology, Herlev Hospital, Herlev, Denmark
  • Nils Brünner Sino-Danish Breast Cancer Research Centre at Section of Pathobiology, Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
  • Bent Ejlertsen Department of Oncology, Rigshospitalet – Copenhagen University Hospital, Copenhagen, Denmark; Danish Breast Cancer Cooperative Group, Copenhagen, Denmark
  • Anne-Vibeke Lænkholm Department of Pathology, Slagelse Hospital, Slagelse, Denmark

DOI:

https://doi.org/10.3109/0284186X.2012.734922

Abstract

Background. The role of tissue inhibitor of metalloproteinases-1 (TIMP-1) in estrogen receptor (ER) positive breast cancer remains to be fully elucidated. We evaluated TIMP-1 as a prognostic marker in patients treated with adjuvant tamoxifen and investigated TIMP-1s association with Ki67 and ER/progesterone receptor (PR)/human epidermal growth factor receptor 2 (HER2) profiles. Material and methods. TIMP-1 expression was evaluated by immunohistochemistry (IHC) on formalin fixed paraffin embedded primary tumor tissue in two independent cohorts comprised of 236 and 192 patients, respectively. Results. No differences in disease free survival (HR 0.98; 95% CI 0.63–1.53; p = 0.92) and overall survival (HR 0.94; 95% CI 0.63–1.43; p = 0.79) were observed according to TIMP-1 status. A significant negative association between TIMP-1 and Ki67 was identified (p = 0.015). TIMP-1 expression did not differ significantly according to ER/PR/HER2 profiles. When analyzed as separate variables PR and HER2 status tended to have a positive but non-significant association with TIMP-1 (PR: p = 0.08; OR 2.54; 95% CI 0.91–7.10, HER2: p = 0.08; OR 0.48; 95% CI 0.21–1.08) whereas ER status was not associated with TIMP-1 expression (p = 0.48; OR 0.68; 95% CI 0.23–1.99). Conclusion. TIMP-1 does not appear to be prognostic in breast cancer patients receiving adjuvant tamoxifen. We identified a negative association between TIMP-1 and Ki67. We did not confirm our previous in vitro findings of a negative association between TIMP-1 and PR.

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2013-01-01

How to Cite

Bjerre, C., Knoop, A., Bjerre, K., Larsen, M. S., Henriksen, K. L., Lyng, M. B., … Lænkholm, A.-V. (2013). Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer. Acta Oncologica, 52(1), 82–90. https://doi.org/10.3109/0284186X.2012.734922

Issue

Vol. 52 No. 1 (2013): Acta Oncologica

Section

Articles